Case Reports
Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab
T.E. Markatseli, E.S. Kaltsonoudis, P.V. Voulgari, A. Zioga, A.A. Drosos
CER220
2009 Vol.27, N°6
PI 0996, PF 0998
Case Reports
Free to view
(click on article PDF icon to read the article)
PMID: 20149320 [PubMed]
Received: 17/02/2009
Accepted : 08/05/2009
In Press: 02/04/2010
Published: 02/03/2010
Abstract
ABSTRACT:Rituximab is a chimeric monoclonal therapeutic antibody which causes depletion of CD20-positive B cells. Apart from its apparent efficacy in the treatment of non-Hodgkin lymphoma and of several rheumatic diseases, it is associated with adverse events including the induction of autoimmune phenomena. We describe here the development of psoriatic skin lesions in a patient with rheumatoid arthritis after the second course of treatment with rituximab. This report supports the hypothesis that autoimmune phenomena may occur by biologic agents and there is a link between B-cell depletion and the induction of psoriatic skin lesions, which were confirmed histologically. However, further studies are needed in order to identify the underlying mechanism, as well as the risk factors associated with rituximab-induced psoriatic skin lesions.
